Chinese Medical Journal最新文献

{"title":"Intestinal metabolites in colitis-associated carcinogenesis: Building a bridge between host and microbiome.","authors":"Yating Fan, Yang Li, Xiangshuai Gu, Na Chen, Ye Chen, Chao Fang, Ziqiang Wang, Yuan Yin, Hongxin Deng, Lei Dai","doi":"10.1097/CM9.0000000000003430","DOIUrl":"10.1097/CM9.0000000000003430","url":null,"abstract":"<p><strong>Abstract: </strong>Microbial-derived metabolites are important mediators of host-microbial interactions. In recent years, the role of intestinal microbial metabolites in colorectal cancer has attracted considerable attention. These metabolites, which can be derived from bacterial metabolism of dietary substrates, modification of host molecules such as bile acids, or directly from bacteria, strongly influence the progression of colitis-associated cancer (CAC) by regulating inflammation and immune response. Here, we review how microbiome metabolites short-chain fatty acids (SCFAs), secondary bile acids, polyamines, microbial tryptophan metabolites, and polyphenols are involved in the tumorigenesis and development of CAC through inflammation and immunity. Given the heated debate on the metabolites of microbiota in maintaining gut homeostasis, serving as tumor molecular markers, and affecting the efficacy of immune checkpoint inhibitors in recent years, strategies for the prevention and treatment of CAC by targeting intestinal microbial metabolites are also discussed in this review.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"1961-1972"},"PeriodicalIF":7.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12369790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Equivalence of SYN008 versus omalizumab in patients with refractory chronic spontaneous urticaria: A multicenter, randomized, double-blind, parallel-group, active-controlled phase III study.","authors":"Jingyi Li, Yunsheng Liang, Wenli Feng, Liehua Deng, Hong Fang, Chao Ji, Youkun Lin, Furen Zhang, Rushan Xia, Chunlei Zhang, Shuping Guo, Mao Lin, Yanling Li, Shoumin Zhang, Xiaojing Kang, Liuqing Chen, Zhiqiang Song, Xu Yao, Chengxin Li, Xiuping Han, Guoxiang Guo, Qing Guo, Xinsuo Duan, Jie Li, Juan Su, Shanshan Li, Qing Sun, Juan Tao, Yangfeng Ding, Danqi Deng, Fuqiu Li, Haiyun Suo, Shunquan Wu, Jingbo Qiu, Hongmei Luo, Linfeng Li, Ruoyu Li","doi":"10.1097/CM9.0000000000003593","DOIUrl":"10.1097/CM9.0000000000003593","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2040-2042"},"PeriodicalIF":7.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12369717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple organ dysfunction and the mortality in sepsis: A multicenter retrospective study.","authors":"Lu Wang, Jieqing Chen, Xiang Zhou","doi":"10.1097/CM9.0000000000003673","DOIUrl":"10.1097/CM9.0000000000003673","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2037-2039"},"PeriodicalIF":7.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12369713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower vs. standard starting dose oral roxadustat for treating anemia in Chinese patients with chronic kidney disease on dialysis: A prospective, randomized clinical trial.","authors":"Yan Tu, Yan Xu, Li Yao, Beiru Zhang, Tiekun Yan, Aiping Yin, Xinzhou Zhang, Min Yang, Jun Liu, Caili Wang, Xiaomei Peng, Jianqin Wang, Wei Niu, Wenqing Jiang, Bi-Cheng Liu","doi":"10.1097/CM9.0000000000003786","DOIUrl":"10.1097/CM9.0000000000003786","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nano drug delivery system based on natural cells and derivatives for ischemic stroke treatment.","authors":"Wei Lv, Yijiao Liu, Shengnan Li, Kewei Ren, Hufeng Fang, Hua Chen, Hongliang Xin","doi":"10.1097/CM9.0000000000003685","DOIUrl":"10.1097/CM9.0000000000003685","url":null,"abstract":"<p><strong>Abstract: </strong>Ischemic stroke (IS) ranks as a leading cause of death and disability globally. The blood-brain barrier (BBB) poses significant challenges for effective drug delivery to brain tissues. Recent decades have seen the development of targeted nanomedicine and biomimetic technologies, sparking substantial interest in biomimetic drug delivery systems for treating IS. These systems are devised by utilizing or replicating natural cells and their derivatives, offering promising new pathways for detection and transport across the BBB. Their multifunctionality and high biocompatibility make them effective treatment options for IS. In addition, the incorporation of engineering techniques has provided these biomimetic drug delivery systems with active targeting capabilities, enhancing the accumulation of therapeutic agents in ischemic tissues and specific cell types. This improvement boosts drug transport and therapeutic efficacy. However, it is crucial to thoroughly understand the advantages and limitations of various engineering strategies employed in constructing biomimetic delivery systems. Selecting appropriate construction methods based on the characteristics of the disease is vital to achieving optimal treatment outcomes. This review summarizes recent advancements in three types of engineered biomimetic drug delivery systems, developed from natural cells and their derivatives, for treating IS. It also discusses their effectiveness in application and potential challenges in future clinical translation.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"1945-1960"},"PeriodicalIF":7.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12369811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hub biomarkers and their clinical relevance in glycometabolic disorders: A comprehensive bioinformatics and machine learning approach.","authors":"Liping Xiang, Bing Zhou, Yunchen Luo, Hanqi Bi, Yan Lu, Jian Zhou","doi":"10.1097/CM9.0000000000003525","DOIUrl":"10.1097/CM9.0000000000003525","url":null,"abstract":"<p><strong>Background: </strong>Gluconeogenesis is a critical metabolic pathway for maintaining glucose homeostasis, and its dysregulation can lead to glycometabolic disorders. This study aimed to identify hub biomarkers of these disorders to provide a theoretical foundation for enhancing diagnosis and treatment.</p><p><strong>Methods: </strong>Gene expression profiles from liver tissues of three well-characterized gluconeogenesis mouse models were analyzed to identify commonly differentially expressed genes (DEGs). Weighted gene co-expression network analysis (WGCNA), machine learning techniques, and diagnostic tests on transcriptome data from publicly available datasets of type 2 diabetes mellitus (T2DM) patients were employed to assess the clinical relevance of these DEGs. Subsequently, we identified hub biomarkers associated with gluconeogenesis-related glycometabolic disorders, investigated potential correlations with immune cell types, and validated expression using quantitative polymerase chain reaction in the mouse models.</p><p><strong>Results: </strong>Only a few common DEGs were observed in gluconeogenesis-related glycometabolic disorders across different contributing factors. However, these DEGs were consistently associated with cytokine regulation and oxidative stress (OS). Enrichment analysis highlighted significant alterations in terms related to cytokines and OS. Importantly, osteomodulin ( OMD ), apolipoprotein A4 ( APOA4 ), and insulin like growth factor binding protein 6 ( IGFBP6 ) were identified with potential clinical significance in T2DM patients. These genes demonstrated robust diagnostic performance in T2DM cohorts and were positively correlated with resting dendritic cells.</p><p><strong>Conclusions: </strong>Gluconeogenesis-related glycometabolic disorders exhibit considerable heterogeneity, yet changes in cytokine regulation and OS are universally present. OMD , APOA4 , and IGFBP6  may serve as hub biomarkers for gluconeogenesis-related glycometabolic disorders.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2016-2027"},"PeriodicalIF":7.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12369747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erianin induces GSDMD-dependent pyroptosis and synergistically enhances doxorubicin efficacy via the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.","authors":"Hanwei Mei, Minghan Qiu, Ruxue Liu, Teng Song, Zhanhua Gao, Qiaonan Zhang, Yayun Wang, Jie Hao, Ming Gao, Zhen Yang, Huaqing Wang","doi":"10.1097/CM9.0000000000003634","DOIUrl":"10.1097/CM9.0000000000003634","url":null,"abstract":"<p><strong>Background: </strong>Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and is characterized by high aggressiveness and rapid growth. Erianin, a natural compound derived from the Chinese herb Dendrobium, has been shown to exhibit anticancer effects in certain types of cancer; however, its role and mechanism of action in DLBCL have not yet been reported. Therefore, this study aimed to investigate the potential of erianin as a therapeutic drug for DLBCL.</p><p><strong>Methods: </strong>The cell counting kit-8 assay, lactate dehydrogenase release assay, flow cytometry, and 5-ethynyl-2'-deoxyuridine (EdU) assay were used to assess the inhibitory effect of erianin on DLBCL cells. RNA sequencing, western blotting, immunofluorescence, and flow cytometry were used to investigate the molecular mechanisms of the effect of erianin on DLBCL cells. Erianin was labeled with biotin or rhodamine, and its target proteins were identified using pull-down assays combined with proteomics, cellular thermal shift assays, and molecular docking. CompuSyn software was used to analyze the combination index of erianin and doxorubicin (DOX) for evaluating their synergistic anti-DLBCL effects. Results from the in vitro experiments were subsequently validated using in vivo experiments.</p><p><strong>Results: </strong>Erianin inhibited the proliferation of DLBCL cells, promoted G2/M phase arrest, and induced cell death. Mechanistically, erianin induced inhibition of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway in DLBCL cells, which led to increased reactive oxygen species (ROS) formation, inflammasome activation, and caspase-1/GSDMD-dependent pyroptosis. Erianin was found to bind to the S100A9 protein, suggesting a potential mechanism through which erianin activates downstream signaling pathways. Moreover, erianin synergistically enhanced the effects of DOX on DLBCL.</p><p><strong>Conclusions: </strong>Our study demonstrates that erianin binds to S100A9 and suppresses the PI3K/AKT signaling pathway in DLBCL cells, thereby elevating ROS levels, activating the inflammasome, and triggering caspase-1/GSDMD-dependent pyroptosis. Moreover, erianin increased the sensitivity of DLBCL cells to DOX both in vitro and in vivo. The effects of erianin on DLBCL imply its potential in the development of promising new drugs against this disease.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted therapies and immunotherapies for unresectable cholangiocarcinoma.","authors":"Shengbai Xue, Weihua Jiang, Jingyu Ma, Haiyan Xu, Yanling Wang, Wenxin Lu, Daiyuan Shentu, Jiujie Cui, Maolan Li, Liwei Wang","doi":"10.1097/CM9.0000000000003705","DOIUrl":"10.1097/CM9.0000000000003705","url":null,"abstract":"<p><strong>Abstract: </strong>Cholangiocarcinoma (CCA) is a fatal malignancy with steadily increasing incidence and poor prognosis. Since most CCA cases are diagnosed at an advanced stage, systemic therapies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, play a crucial role in the management of unresectable CCA. The recent advances in targeted therapies and immunotherapies brought more options in the clinical management of unresectable CCA. This review depicts the advances of targeted therapies and immunotherapies for unresectable CCA, summarizes crucial clinical trials, and describes the efficacy and safety of different drugs, which may help further develop precision and individualization in the clinical treatment of unresectable CCA.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"1904-1926"},"PeriodicalIF":7.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12369749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Itaconate derivative 4-OI inhibits M1 macrophage polarization and restores its impaired function in immune thrombocytopenia through metabolic reprogramming.","authors":"Qiang Liu, Anli Liu, Shaoqiu Leng, Xiaoyu Zhang, Xiaolin Wang, Zhang Cheng, Shuwen Wang, Jun Peng, Qi Feng","doi":"10.1097/CM9.0000000000003586","DOIUrl":"10.1097/CM9.0000000000003586","url":null,"abstract":"<p><strong>Background: </strong>Macrophage polarization anomalies and dysfunction play a crucial role in the pathogenesis of immune thrombocytopenia (ITP). Itaconate is a Krebs cycle-derived immunometabolite synthesized by myeloid cells to modulate cellular metabolism and inflammatory responses. This study aimed to evaluate the immunoregulatory effects of an itaconate derivative on macrophages in patients with ITP.</p><p><strong>Methods: </strong>Peripheral blood-derived macrophages from patients with ITP and healthy controls were treated with 4-octyl itaconate (4-OI), a derivative of itaconate that can penetrate the cell membrane. Macrophage polarization, antigen-presenting functions, and phagocytic capability were measured via flow cytometry and enzyme-linked immunosorbent assay (ELISA). Macrophage glycolysis in patients with ITP and the metabolic regulatory effect of 4-OI were detected using a Seahorse XFe96 Analyzer. An active murine model of ITP was used to evaluate the therapeutic effects of 4-OI in vivo .</p><p><strong>Results: </strong>4-OI reduced the levels of CD80 and CD86 in M1 macrophages and suppressed the release of tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 pro-inflammatory cytokines, suggesting that 4-OI could hinder the polarization of macrophages toward an M1 phenotype. We found that 4-OI pretreated M1 macrophages reduced the proliferation of CD4 + T cells and promoted the differentiation of regulatory T cells. In addition, after 4-OI treatment, the phagocytic capacity of M1 macrophages toward antibody-coated platelets decreased significantly in patients with ITP. In addition, the glycolytic function of M1 macrophages was elevated in individuals with ITP compared to those in healthy controls. 4-OI treatment downregulated glycolysis in M1 macrophages. The glycolysis inhibitor 2-deoxy-d-glucose (2-DG) also inhibited the polarization of M1 macrophages and restored their functions. In vivo , 4-OI treatment significantly increased platelet counts in the active ITP murine model.</p><p><strong>Conclusions: </strong>Itaconate derivative 4-OI inhibited M1 macrophage polarization and restored impaired functions through metabolic reprogramming. This study provides a novel therapeutic option for ITP.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"2006-2015"},"PeriodicalIF":7.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12369833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P4HA1 mediates YAP hydroxylation and accelerates collagen synthesis in temozolomide-resistant glioblastoma.","authors":"Xueru Li, Gangfeng Yu, Xiao Zhong, Jiacheng Zhong, Xiangyu Chen, Qinglong Chen, Jinjiang Xue, Xi Yang, Xinchun Zhang, Yao Ling, Yun Xiu, Yaqi Deng, Hongda Li, Wei Mo, Yong Zhu, Ting Zhang, Liangjun Qiao, Song Chen, Fanghui Lu","doi":"10.1097/CM9.0000000000003679","DOIUrl":"10.1097/CM9.0000000000003679","url":null,"abstract":"<p><strong>Background: </strong>Temozolomide (TMZ) resistance is a significant challenge in treating glioblastoma (GBM). Collagen remodeling has been shown to be a critical factor for therapy resistance in other cancers. This study aimed to investigate the mechanism of TMZ chemoresistance by GBM cells reprogramming collagens.</p><p><strong>Methods: </strong>Key extracellular matrix components, including collagens, were examined in paired primary and recurrent GBM samples as well as in TMZ-treated spontaneous and grafted GBM murine models. Human GBM cell lines (U251, TS667) and mouse primary GBM cells were used for in vitro studies. RNA-sequencing analysis, chromatin immunoprecipitation, immunoprecipitation-mass spectrometry, and co-immunoprecipitation assays were conducted to explore the mechanisms involved in collagen accumulation. A series of in vitro and in vivo experiments were designed to assess the role of the collagen regulators prolyl 4-hydroxylase subunit alpha 1 (P4HA1) and yes-associated protein (YAP) in sensitizing GBM cells to TMZ.</p><p><strong>Results: </strong>This study revealed that TMZ exposure significantly elevated collagen type I (COL I) expression in both GBM patients and murine models. Collagen accumulation sustained GBM cell survival under TMZ-induced stress, contributing to enhanced TMZ resistance. Mechanistically, P4HA1 directly binded to and hydroxylated YAP, preventing ubiquitination-mediated YAP degradation. Stabilized YAP robustly drove collagen type I alpha 1 ( COL1A1) transcription, leading to increased collagen deposition. Disruption of the P4HA1-YAP axis effectively reduced COL I deposition, sensitized GBM cells to TMZ, and significantly improved mouse survival.</p><p><strong>Conclusion: </strong>P4HA1 maintained YAP-mediated COL1A1 transcription, leading to collagen accumulation and promoting chemoresistance in GBM.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"1991-2005"},"PeriodicalIF":7.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12369758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}